PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumors PLN-101095 accelerated development plan underway with initiation of Phase 1b indicatio ...

The "Checkpoint Inhibitor Refractory Cancer Drugs Market -- Growth, Share, Opportunities & Competitive Analysis, 2025 -- 2032" report has been added to the Credence Research Inc. offering. The global ...

PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumorsPLN-101095 accelerated ...

In a significant breakthrough in reproductive medicine, doctors at a private hospital in New Delhi have reported two successful live births after treating severe Asherman's Syndrome using umbilical ...

Doctors in New Delhi have achieved two successful live births by treating severe Asherman's Syndrome with umbilical cord-derived stem cells. The pioneering procedure offers new hope to women suffering ...

NorthStrive Fund II LP ("NorthStrive Fund", "we", "our" or "us"), a subsidiary of NorthStrive Companies Inc., headquartered in Newport Beach, California, is a significant shareholder of Bluejay ...

The phase 3 SUCCESSOR-2 trial shows mezigdomide-based therapy improves PFS in R/R multiple myeloma patients previously exposed to lenalidomide.

Glo-BNHL global trial opens sites in Netherlands and Austria to trial multiple new treatments for B-cell Non-Hodgkin Lymphoma ...

BTK inhibitor monotherapy is foundational across several B-cell malignancies, with newer, more selective agents designed to preserve efficacy while improving tolerability relative to first-in-class ...

Access the Moleculin CEO Corner here HOUSTON, March 11, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has released the next ...